USPTO serial 88797477
ORIGAMI
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- SHINN, LAUREN DONGMI
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ORIGAMI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Katrin Lewertoff
Katrin Lewertoff Ferdinand IP, LLC1221 Post Road EastSuite 302Westport, CT 06880Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biotechnological products, namely, chemicals for use in biotechnological product development for scientific purposes; Biological material, namely, biochemical preparations for scientific purposes; Cells for scientific purposes; Eukaryotic cells for scientific purposes; Prokaryotic cells for scientific purposes; Stem cells for scientific purposes; Living cells for scientific purposes; Reagents for scientific purposes; Diagnostic reagents for scientific use; Bacteria for scientific purposes; Diagnostic biomedical compounds, namely, peptide substrates used in analyzing and detecting certain toxins for scientific purposes; Nucleic acid for laboratory use; Proteins for use in manufacture; Small molecules being chemical compounds for use in patterning at nano scale or near nano scale | ACTIVE | — |
| 005 | Biotechnological products, namely, diagnostic reagents, medicines for gene therapy for the treatment of genetic diseases and/or cancer for medical purposes; Medicines for treating genetic disorders; Nanoparticles carrying drugs and nucleic acids for treating cancers; Synthetic peptide based nanoparticles for gene therapy for the treatment of genetic diseases and/or cancer; protein-based nanoparticles for gene therapy for the treatment of genetic diseases and/or cancer; cell-based therapeutic products, namely, vaccines; Pharmaceutical compounds for gene therapy for the treatment of genetic diseases and/or cancer; Biological material, namely, biological diagnostic preparations for gene therapy for the treatment of genetic diseases and/or cancer; Nucleic acids for medical purposes; proteins arrays for medical diagnosis purposes; cells for medical use; self-replicating nucleic acids for medical purposes; peptides for gene therapy for the treatment of genetic diseases and/or cancer; Eukaryotic cells for medical purposes; Prokaryotic cells for medical purposes; Stem cells for medical purposes; Living cells for medical purposes; Pharmaceutical compounds for gene therapy for the treatment of genetic diseases and/or cancer, vaccines, diagnostic rubbing compounds for medical purposes; Delivery vehicles, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Reagents for medical purposes; Diagnostic reagents for medicinal use; Bacteria for medical purposes; Diagnostic bacteria for medicinal use; Biochemical compounds for gene therapy for the treatment of genetic diseases and/or cancer for medical and veterinary application; Vaccines for medical and veterinary use | ACTIVE | — |
| 009 | Biotechnological products, namely, bio-chips for scientific purposes | ACTIVE | — |
| 042 | Consultancy in the field of biotechnology; Research and development in the field of biotechnology; Research and development in the field of immunology; Research and development in the field of biochemistry | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Origami Biosciences Inc.
- Other trademarks owned by Origami Biosciences Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named ORIGAMI
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 7, 2023 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 7, 2023 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 8, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 6, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Dec 6, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| Dec 6, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 28, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 24, 2022 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 24, 2022 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 24, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 1, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 29, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 29, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Nov 29, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 6, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 23, 2021 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Feb 10, 2021 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jan 12, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 12, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 23, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 4, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 2, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 2, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 2, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 2, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 10, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 9, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 9, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 27, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| May 15, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 15, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 15, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 6, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 20, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 18, 2020 | NWAP | NEW APPLICATION ENTERED | — |